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Abstract
Background: Trigeminal neuralgia (TN) is an orofacial condition defined by reoccurring, spontaneous, short-lived
but excruciating stabbing pain. Pharmacological interventions constitute the first-line treatment for TN, with
antiepileptic drugs commonly prescribed. People treated for TN pain with antiepileptic drugs describe cognitive
and motor difficulties affecting activities of daily living, and report poorer quality of life. We undertook the first
comprehensive objective evaluation of sensorimotor and cognitive performance in participants being treated for TN
pain with antiepileptic drugs relative to age-matched controls.
Methods: Participants (43 TN, 41 control) completed a battery of sensorimotor (steering, aiming and tracking) and
cognitive (working memory, processing speed, inhibition) tasks.
Results: The TN group performed significantly worse than controls on the sensorimotor tracking and aiming tasks
and across all cognitive measures.
Conclusions: The data explain why patients treated with antiepileptic drugs report impairment when conducting
activities of daily living (given the need for cognitive and motor capability within most of these). The study is an
important first step in: (i) ensuring there is adequate information on the impact of pharmacological treatment; (ii)
identifying measures to determine optimal medication dosage and track change over time; (iii) creating an
evidence base that could allow scientific justification of alternative pain treatment options for TN (e.g. the costs/
benefits of surgery).
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Background
Trigeminal neuralgia (TN) is a unilateral orofacial pain
condition characterised by excruciating electric shock-
like pains, abrupt in onset and termination, limited to
one or more distributed divisions of the trigeminal nerve
[1]. TN-related pain is unpredictable in attack and re-
mission frequency, can be triggered by innocuous stimuli
(e.g. cold wind), and can greatly affect quality of life;
causing sleep disturbance, depression, anxiety, impairing
activities of daily living, and even suicide attempts, with
an obvious impact on the individual but also on family
and friends, particularly in the instance of bereavement
after the suicide of a loved one [2–7].
Anti-epileptic drugs (AEDs) are the first-line treatment
for TN pain, and recent European guidelines for the
treatment of TN recommend carbamazepine and oxcar-
bazepine in the first instance [8]. AEDs usually offer ini-
tial pain relief by reducing the frequency and intensity of
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pain paroxysms [9–11], but their efficacy appears to de-
crease over time [12–15] and tolerance can be low with
side-effects causing medication to be stopped or reduced
to a level insufficient for pain relief [16, 17].
AEDs work by decreasing neuronal sensitivity [14] so
it is unsurprising that they can disrupt function. Im-
paired cognitive function (e.g. reaction time, response
inhibition, verbal fluency, attention, memory, mood) has
been linked to AED use in patients with epilepsy [18–
20], and healthy controls [21, 22]. Polypharmacy and
higher dosage are related to more extreme side effects
[23]. AEDs have also been linked to impaired motor
function [24] including problems with balance, dizziness,
gait, dexterity, ataxia, diplopia, dyskinesias, myoclonus,
and parkinsonism-tremor [25, 26]. AEDs are amongst
the most likely drugs to be linked with cerebellar ataxia
(characterised by impaired motor coordination and
problems with gait, balance, speech and eye movements
[27–29]). Ataxia tends to disappear after discontinuation
(although symptoms may persist, particularly with pro-
longed use [27]). Again, most AEDs are associated with
dose-dependent risk [25, 27].
The frequently reported side effects of AEDs in the TN
population have not been well quantified via objective mea-
sures, but studies suggest a profoundly negative impact. In-
terviews, clinical note analysis, and questionnaires have
shown AEDs used for TN are often accompanied by self-
reported tiredness, disturbed sleep, concentration difficul-
ties, unsteadiness, handwriting problems, mental arithmetic
struggles, and poor memory [6, 16, 30]. One study [31]
measured the effects of carbamazepine on 22 patients to
provide objective validation of such verbal reports. Delcker
et al. [31] found postural stability, mean reaction time of
tonic alertness and attention were influenced by dose. This
is an important result but only captured one specific motor
behaviour in a small number of patients.
In summary, studies suggest cognitive and sensori-
motor side effects in TN patients taking AEDs for pain,
but these verbal reports require validation and objective
quantification. The current absence of quantifiable and
objective measures of cognitive and sensorimotor func-
tion make it difficult to provide individuals with TN with
reliable information about the potential impact of their
condition. In addition, clinicians have no reliable guide
to the optimum pharmacological dosage, or means of
tracking how the impact of the medication changes over
time. Finally, the lack of reliable evidence on the side ef-
fects of current pharmacological treatment means that
justification for instigating a randomized clinical trial of
surgery does not exist as the grounds for early surgical
intervention are weakened if there is a satisfactory
pharmacological treatment.
We aimed to compare the performance of AED-
medicated individuals with TN to age-matched controls
across a range of tasks in order to provide objective
measures of sensorimotor and cognitive function in pa-
tients being treated for TN. Our sensorimotor measures
captured critical visuomotor transformations (tracking,
steering, and aiming) that underlie numerous activities
of daily living. Likewise, we selected a range of cognitive
tasks that captured core abilities (memory, inhibition and
processing speed) widely recognized as providing the fun-
damental building blocks of higher order cognitive func-
tion. The weight of subjective reports of cognitive
problems led us to expect the TN population to have diffi-
culties on a number of our cognitive tasks – though it was
not clear whether the nature of the difficulties would be
selective or impact on all core cognitive abilities. It seemed
reasonable to predict that performance on our tracking
task (which taps into cerebellar function) would be detri-
mentally affected in the medicated TN participants com-
pared to controls given the well-established association
between AEDs and cerebellar ataxia (and the fact that pa-
tients often report postural disturbance). It was not pos-
sible to predict a priori the potential impact of AEDs on
the steering and aiming tasks.
Method
Participants
Forty two participants with TN (28 females, 14 males,
age range 24–84 years (M = 60.64, SD = 15.67) were re-
cruited via a voluntary sampling method using associa-
tions with University College London Hospitals (UCLH)
and the Trigeminal Neuralgia Association UK (TNA
UK). All testing took place in the School of Psychology
at the University of Leeds, in offices arranged by the
TNA UK, or in a clinic through JZ at UCLH. Inclusion
criteria were comprised of being over 18 years old, hav-
ing a diagnosis of TN, taking AEDs for pain manage-
ment, able to consent themselves personally into the
study, and able to follow simple verbal instructions given
in English by the researcher. Participants were excluded
from the study if they had concurrent musculoskeletal
problems or a neurological condition, such as Parkin-
son’s Disease or Arthritis, that would disrupt their ability
to perform the motor tasks or confound their interpret-
ation of the tasks by impairing their cognitive, motor or
perceptual functioning. Forty six people were initially re-
cruited and tested, but three were later excluded as they
were not currently taking AED medication for pain man-
agement. One further participant had to be excluded
due to suffering a pain attack during testing and was
therefore unable to complete the tests.
Forty one control participants (33 females, 8 males,
age range of 24–90 years (M = 60.53, SD = 15.77)) were
recruited and age matched within ±2 years of the TN
participants apart from one participant (aged 90) who
was 6 years older than their TN age-match. Inclusion
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criteria consisted of being over 18 years old, having no
diagnosis or history of TN, can consent themselves per-
sonally into the study, can follow simple verbal instruc-
tions given in English by the researcher. Control
participants were excluded if they were taking AEDs for
any reason, had concurrent health problems or neuro-
logical conditions that would disrupt their ability to per-
form the motor tasks or confound their interpretation of
the tasks by impairing their cognitive, motoric or per-
ceptual functioning. Recruitment was on a voluntary
basis via numerous methods; the Successful Aging Panel
in the School of Psychology at the University of Leeds,
word of mouth, or ‘bring a friend’ scheme where they
accompanied a TN participant. Forty-two control partic-
ipants were initially recruited and tested, but one indi-
vidual was removed because they were age-matched to
the TN participant who could not complete the tasks.
All participants were free from any musculoskeletal
problems that would hinder them using a handheld sty-
lus. Ethical approval was granted from the School of
Psychology Research Ethics Committee at the University
of Leeds (REF: PSC-482) and accounted for all control
participants and TN participants recruited via the TNA
UK. NHS ethical approval (REF: 07/MRE01/38) covered
all participants recruited through author JZ via UCLH.
Participants provided written consent prior to taking
part.
Materials
TN participants were required to fill out a questionnaire
containing 12 questions on the nature of their TN pain,
their medications, and any noticeable side effects. Medi-
cations are summarised in Table 1.
The sensorimotor battery contained tasks chosen to
assess three key sensorimotor transformations that
underpin a wide range of activities of daily living/motor
tasks (steering, aiming and tracking). The tests were pre-
sented using the Clinical Kinematic Assessment Tool
(CKAT): a tool that provides objective measures of sen-
sorimotor performance [32]. CKAT presents interactive
visual stimuli on a tablet laptop screen whilst recording
participants’ kinematic responses to these stimuli. The
CKAT test was implemented on a Lenovo tablet port-
able computer (ThinkPad Core™ M-5Y10c, screen size:
215x299mm, 1920 × 1080 pixels, 32 bit colour, 60 Hz re-
fresh rate) with a pen-shaped stylus (140x9mm diam-
eter) used as an input device. The CKAT software
records stylus position to capture various kinematic
measures (e.g. movement time, peak speed) to provide
information about the accuracy and efficiency of partici-
pants’ movements. For a full overview of the CKAT soft-
ware and tests see [32, 33].
The cognitive battery contained tasks chosen to assess
a variety of abilities central to cognitive ability e.g.
working memory, processing speed, and inhibition;
widely recognised as providing the building blocks of
higher order cognitive function. The tasks chosen also
represented broad domains where TN patients have re-
ported negative effects of medication [6, 34]. The tasks
were completed on the tablet, with participants using
finger touch to submit their responses. Headphones
were used for the forward digit recall and backward digit
recall tasks. Further detail on the CKAT and Cognitive
Battery tasks is given below.
Procedure
Once informed consent was gained, participants com-
pleted the questionnaire. For the sensorimotor and cog-
nitive batteries, participants were seated at a table with
the tablet screen detached from the keyboard of the lap-
top. This was placed in landscape orientation in front of
them. Each participant completed the entire battery of
tests in a single session lasting approximately 45 min.
The tests were completed by all participants in the fol-
lowing fixed order.
Sensorimotor battery
This battery contains three tasks (tracking, aiming and
steering), lasting approximately 12–15 min in total.
Figure 1 shows a graphical representation of the tasks.
Tracking Participants were required to track a moving
green circle displayed on the screen by keeping the tip
of the stylus within the area of the green circle. The cir-
cle moved in a ‘figure-of-8’ pattern completing nine rev-
olutions, with the speed of movement increasing after
every three revolutions. The tracking task contained two
consecutive trials; an unguided trial where the path can’t
be seen, and a guided trial (lasting approximately 63 s
each). A mean RMSE was calculated for each guide and
speed condition. Lower scores indicate better
performance.
Aiming Participants were required to move the stylus as
quickly as possible (without the stylus losing connection
with the screen) from a start position to a green dot that
appeared. Once the tip of the stylus reached the green
circle, that target disappeared, and a new target appeared
in a different location. All targets appeared at a fixed dis-
tance from each other. The participant moved from
target-to-target until they had made a total of 75 discrete
aiming movements, which took approximately 2–4 min.
Movement time (MT) in seconds (s) (the time between
arrival at 1 target dot and arrival at the next) was re-
corded, and the median MT for the first 50 aiming
movements is reported. Shorter MTs indicate superior
performance.
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Table 1 Type and dosage (mg) of medication by participant
Current Medical Management
Participant AED Type Therapy Type CBZ/TEG OXC LTG/LAM GBP PGB PHE Non-AEDs
TN0001 1 1 800
TN0002 3 2 200 1200
TN0003 3 1 200
TN0004 3 2 X X
TN0005 3 2 600 100
TN0006 1 1 700 10(A)
TN0007 1 1 1100 20(A)
TN0008 2 1 25+
TN0009 1 1 200
TN0010 2 1 900 30(A)
TN0011 3 2 400 1500
TN0012 2 1 4*
TN0014 3 1 400
TN0016 3 2 75 300
TN0017 3 2 450 250 275
TN0018 1 1 900
TN0019 1 1 500
TN0020 3 2 800 200
TN0021 3 2 300 300
TN0022 1 1 1800
TN0023 3 2 2800 500 225(LX), 10(LP)
TN0024 1 1 500
TN0025 1 1 12*
TN0026 3 2 900 100
TN0027 3 2 250–2400 900
TN0028 2 1 900 150(A)
TN0029 1 1 50
TN0030 3 1 400
TN0032 3 1 275
TN0033 1 1 150
TN0034 1 1 800
TN0036 2 1 1800
TN0037 1 1 1200
TN0038 1 1 1800
TN0039 1 1 200
TN0040 1 1 200
TN0041 2 1 3600
TN0042 3 2 1500 300
TN0043 3 2 1200 400
TN0044 3 2 300 1500 20(A), 180(B)
TN0045 1 1 600
TN0046 3 2 700 100
All units represent milligrams (mg) per day, unless otherwise stated. AEDs: CBZ Carbamazepine, TEG Tegretol, OXC Oxcarbazepine, LTG Lamotrigine, LAM Lamictal,
GBP Gabapentin, PGB Pregabalin, PHE Phenytoin. Non-AEDs: A Amitriptyline, B Baclofen, LX Levothyroxine, LP Lisinonpril
Types of AED: 1 = Sodium only, 2 = Calcium only, 3 = Sodium and Calcium
Type of drug therapy: 1 = Monopharmacy, 2 = Polypharmacy
*Dosage unknown, participant provided number of tablets only (e.g. 12 tablets)
+Dosage is taken every two days
XParticipant provided drug name but not dose
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Steering Participants were instructed to keep the tip
of the stylus within a narrow pathway consisting of
two parallel lines whilst moving the stylus from a
‘Start’ to a ‘Finish’ position on the screen. Speed was
controlled by instructing participants to keep their
stylus within a ‘pacing box’, which moved along the
path sequentially in five second intervals. Participants
completed two different paths (one the reverse of the
other) and each took approximately 40s to complete.
Path accuracy (measured as the difference between
the stylus and an idealised reference path) and time
were recorded. Penalized path accuracy (pPA, mm)
was calculated for each path using the following for-
mula: pPA = Path Accuracy * (1 + ((Movement time -
36)/36)). This provides a measure of accuracy that
takes movement time into account to control for
Fig. 1 Sensorimotor Battery: a Tracking, b Aiming and c Steering, taken from Flatters et al. (2014). a Tracking: Left demonstrates the without-
guide tracking trial (the dotted line indicates the pattern of movement, but participants did not see this line). Right shows the tracking trial with a
guide. b Aiming: Arrows demonstrate direction of movement participants made but this is not visible to the participant. The 4th image shows
the repeated movements that the participants made, with the numbers demonstrating which dot appeared in which sequence. c Steering: Left
shows tracing path A and right shows tracing path B. The square box is the ‘pace’ box and the thick black lines demonstrate the pathway area
that participants were expected to stay within
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situations where participants do not remain within
the pacing box.
Cognitive battery
This battery contained five tasks designed to measure
simple phonological working memory, complex
phonological working memory, visuospatial working
memory, processing speed (PS) and inhibition. All
five tasks were preceded by a practice trial. Partici-
pants were asked to interact with the visual stimuli
on the screen using finger touch. The whole battery
took approximately 20–30 min to complete. Tasks
were always presented to participants in the same
order following standardised instructions.
Forward digit recall (FDR) A sequence of numbers
was presented through headphones and participants
were asked to recall these numbers by touching the
appropriate boxes on the screen (9 boxes ordered se-
quentially from 1 to 9), in the order that they were
originally presented. As the task progressed, the se-
quence length increased incrementally from three to
six. There were four trials at each sequence length,
with 16 trials in total over the course of the task. Re-
action time (s) and response accuracy (correct or
incorrect) was recorded for each item. Mean propor-
tion correct (primary outcome variable) and mean
RT (secondary outcome variable) for each sequence
length is reported.
Backward digit recall (BDR) Similar to FDR, but par-
ticipants were asked to recall these numbers in reverse
order. As the task progressed, the sequence length in-
creased incrementally from two to five.
Corsi block tapping At the start of the task nine ran-
domly arranged blue squares were presented on the
screen. A random and unique sequence of boxes flashed
yellow and the participant was required to remember
this order and, once the sequence had finished, respond
by tapping the blue boxes in the order that they had
changed colour. The difficulty was raised by increasing
the sequence lengths, starting with three squares and
ending with six. This task had a total of 16 trials, with
four different sequences presented for each level of diffi-
culty/sequence length. Reaction time (s) and response
accuracy (correct or incorrect) was recorded for each
item. Mean proportion correct (primary outcome vari-
able) and mean RT (secondary outcome variable) for
each sequence length is reported.
Processing speed (PS) Red circles, red triangles and
blue circles were presented on the screen. The partici-
pants were asked to identify how many red circles were
present on the screen and respond by tapping the box
located at the bottom of the screen containing the cor-
rect number. Participants were requested to carry out
each of the 18 trials as quickly and accurately as pos-
sible. Reaction time (s) and response accuracy (correct
or incorrect) was recorded for each item. Mean RT for
correct trials is reported.
Inhibition (flankers) The participants were presented
with a line of five arrows in the centre of the screen.
They were required to identify the direction of the
middle arrow in two different conditions, where the
remaining four arrows were either pointing in the
same (congruent) or opposite (incongruent) direction
as the middle arrow. Participants were required to an-
swer as quickly and accurately as possible. Mean reac-
tion time (s) for the congruent and incongruent trials
is reported.
Statistical analyses
This was a mixed research design with various inde-
pendent (IV) and dependent (DV) variables depending
on the task (see Table 2 for details). The statistical soft-
ware package JASP [35] was used to explore the CKAT
battery and Cognitive battery RT data, and SPSS [36]
used for the Cognitive battery proportion correct ana-
lyses. For all tasks, group (TN/Control) was treated as a
between subjects variable and all other IVs as within
subjects variables.
CKAT battery and cognitive battery reaction time data
Mixed ANOVAs were used to explore Tracking, Steer-
ing, FDR RT, BDR RT, Corsi RT, and Flankers RT. Aim-
ing and Processing speed contained only one
independent variable (Group) for which an independent
t-test and Mann-Whitney test were used (the latter due
to deviations from normality). Outliers for the CKAT
battery tasks were removed if they were two standard
Table 2 Experimental Tasks and Independent (IV) and
Dependent (DV) Variables
Task IV DV
Tracking Group/ Guide/ Speed RMSE
Aiming Group RT (s)
Steering Group/ Pathway pPA (mm)
BDR Group/ Sequence Length Proportion Correct / RT (s)
FDR Group/ Sequence Length Proportion Correct / RT (s)
Corsi Group/ Sequence Length Proportion Correct / RT (s)
Inhibition Group/ Congruency RT (s)
PS Group RT (s) for correct trials
BDR Backward Digit Recall, FDR Forward Digit Recall, PS Processing Speed,
RMSE Root Mean Square Error, RTs Reaction Time, pPA Penalised Path Accuracy
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deviations away from the mean (24 trials in total). Four
further trials were removed due to technical failures.
Where Mauchly’s test of sphericity was violated, a
Greenhouse-Geisser correction was applied. When
Levene’s test for homogeneity of variance was violated
(unsurprisingly often given the nature of the variability
of the TN sample) this is reported, and the data were
transformed using a reciprocal transform to achieve
homogeneity. The data displayed in the figures is the
original pre-transform data. Finally, where pairwise com-
parisons were used to explore significant main effects, a
Bonferroni Holm correction was applied, and only inter-
actions involving group, and therefore relevant to the
specific research question, are explored for the sake of
brevity.
Cognitive battery proportion correct
The proportion correct data (for FDR, BDR and Corsi)
could not be transformed to correct for significant devia-
tions from homogeneity of variance. For this reason, we
categorised participants as either high or low performers
using the mean performance across all participants for
each sequence length as the cut off between high and
low performance. We then used a Chi Squared χ2 test to
check for associations between group and performance
(high or low). The data displayed in the figures is the
original pre-categorisation data.
Additional analyses
Finally, we took the opportunity to conduct some post-
hoc analyses on the effects of monopharmacy (n = 15) vs
polypharmacy (n = 27) and AED type within the medi-
cated TN group (see Table 1 for details). We compared
participants taking sodium blockers only (n = 17) to
those taking drugs that blocked both calcium and so-
dium (n = 19). There were too few people taking calcium
blockers alone (n = 6) to include as a group. Once more,
group was treated as an independent variable and the
rest of the design and all conducted analyses remained
the same. We also tested for an association between
dose and performance on each task. We calculated the
total quantity of AED medication (mg) for each partici-





A 2 × 2 × 3 mixed ANOVA was conducted to analyse the
effect of group (TN/Control), guide (with guide/no
guide) and speed (slow/medium/fast) on RMSE. A
Fig. 2 Tracking. Mean root mean square error (RMSE) for both groups (Control = circles, TN = triangles) across all speeds. The top plot shows the
No Guide condition and the bottom plot the With Guide condition
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reciprocal transform was used to achieve homogeneity
of variance and a mixed ANOVA was performed on
these data. Raw scores pre-transform can be seen in
Fig. 2. The Levene’s test remained significant for the ‘Fast
With Guide’ condition. Data were available from 36 TN
participants and 36 Controls. A main effect of group
emerged [F (1,70) = 7.44; p < 0.01, η2 = 0.10] with RMSE
being significantly higher in the TN group. Main effects
for Guide [F (1,70) = 185.99; p < 0.01, η2 = 0.73] and Speed
[F (1.11,78.61) = 1915.63; p < 0.001, η2 = 0.96] emerged,
with RMSE significantly increasing (p < 0.001) as the speed
of the dot increased. There was also a Speed x Guide
interaction [F (1.25, 87.52) =187.44; p < 0.001, η2 = 0.73].
Aiming
An independent t-test was used to test for a difference
in movement time (s) between the two groups. Data
were included from 40 control and 40 TN participants.
Movement Time (MT) was significantly longer for the
TN participants (mean = 1.33 s, SD = 0.18) than the con-
trols (mean = 1.24 s, SD = 0.20) [t (78) = 2.10, p < 0.05,
Cohen’s d = − 0.47].
Steering
A 2 × 2 mixed ANOVA was conducted to analyse the ef-
fects of group (TN/Control) and path (path A and B) on
penalised path accuracy. Data were included from 39
control and 40 TN participants (Control path A: mean =
1.33 s, SD = 0.54; Control path B: mean = 1.23 s, SD =
0.45; TN path A: mean = 1.40s, SD = 0.54; TN path B:
mean = 1.31 s, SD = 0.49). No main effects or interactions
emerged [Group F (1,77) = 0.561, p = 0.456, η2 = 0.007;
path F (1,77) = 2.849, p = 0.1, η2 = 0.036; Group x path F
(1,77) = 0.001, p = 0.970, η2 = 0.00].
Cognitive battery
Forward digit recall (FDR)
Proportion correct A χ2 test was used to test for an as-
sociation between participant group (TN/Control) and
obtaining a high proportion correct score. Participants
were at ceiling for trials with a sequence length of three so
these cannot be analysed. For trials with a sequence length
of four there was no significant association between the
participant group (TN/Control) and whether they were
likely to get a high score [χ2 (1) = 1.89, p = 0.14, odds ra-
tio = 2.25]. For trials with a sequence length of five or six
there was a significant association between the group the
participants were in (TN/Control) and whether or not
they were likely to get a high score [length 5: χ2 (1) =
7.623, p < 0.01, length 6: χ2 (1) = 5.529, p < 0.05]. Based on
the odds ratio, the odds of getting a high score were 3.97
Fig. 3 Forward Digit Recall (FDR); Backward Digit Recall (BDR); Corsi Block Tapping. Mean proportion correct (column 1) and mean reaction time
(column 2) for both groups (Control = circles, TN = triangles) across all sequence lengths
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(sequence length 5) and 2.93 (sequence length 6) times
higher if the person was a Control participant than a TN
participant. Raw scores pre categorisation can be seen in
Fig. 3.
RT For the reaction time (RT) data a reciprocal trans-
form was used to achieve homogeneity of variance and a
2 × 4 mixed ANOVA performed on these data to analyse
the effect of group (TN/Control), and sequence length
(3,4,5,6) on RT. Raw mean RT scores pre-transform can
be seen in Fig. 3. A significant main effect of group
emerged [F (1,81) = 17.94, p < 0.001, η2 = 0.181] with RTs
longer for the TN group than Control group. There was
also a main effect of sequence length [F (2.51, 203.64) =
14.96, p < 0.001, η2 = 0.15] caused by significant differ-
ences between all sequence lengths (p < 0.05) apart from 3
and 4 (p = 0.09). No group x sequence length interaction
emerged [F (2.51, 203.64) = 2.09, p = 0.114, η2 = 0.02].
Backward digit recall (BDR)
Proportion correct Participants were at ceiling for trials
with a sequence length of two, so these cannot be ana-
lysed. For trials with a sequence length of four there was
no significant association between participant group
(TN/Control) and whether they were likely to get a high
score [χ2 (1) = 3.046, p = 0.064, odds ratio = 2.25]. For tri-
als with a sequence length of three and five there was a
significant association between the group the partici-
pants were in (TN/Control) and whether or not they
were likely to get a high score [length 3: χ2 (1) = 3.013,
p < 0.05, length 5: χ2 (1) = 6.467, p < 0.05]. Based on the
odds ratio, the odds of getting a high score were 3.23
(sequence length 3) and 3.17 (sequence length 5) times
higher if the person was a control participant than a TN
participant. Raw scores pre categorisation can be seen in
Fig. 3.
RT For the reaction time (RT) data a reciprocal trans-
form was used to achieve homogeneity of variance and a
2 × 4 mixed ANOVA performed on these data to analyse
the effect of group (TN/Control), and sequence length
(2,3,4,5,) on RT. Raw mean RT scores pre-transform can
be seen in Fig. 3. A significant main effect of group
emerged [F (1,81) = 18.41,p < 0.001, η2 = 0.185] with RTs
longer for the TN group than Control group. There was
also a main effect of sequence length [F (2.71, 219.78) =
110.98, p < 0.001, η2 = 0.57] caused by significant differ-
ences between all sequence lengths (all p < 0.001). A
group x sequence length interaction emerged [F (2.71,
219.78) = 2.96, p < 0.05, η2 = 0.015] supporting what can
be seen in the figure: that group differences increased as
sequence length increased.
Corsi block tapping (Corsi)
Proportion correct For trials with a sequence length of
three there was no significant association between the
group a participant was in (TN/Control) and whether
they were likely to get a high score [χ2 (1) = 0.863, p =
0.25, odds ratio = 1.59]. For trials with a sequence length
of four, five and six there was a significant association
between the participant group (TN/Control) and
whether or not they were likely to get a high score
[length 4: χ2 (1) = 5.23, p < 0.05, length 5: χ2 (1) = 6.37,
p < 0.01, length 6: χ2 (1) = 3.49, p < 0.05]. Based on the
odds ratio, the odds of getting a high score were 2.81
(sequence length 4), 3.12 (sequence length 5), and 2.30
(sequence length 6) times higher if the person was a
control participant than a TN participant. Raw scores
pre categorisation can be seen in Fig. 3.
RT A 2 × 4 mixed ANOVA was conducted to analyse
the effect of group (TN/Control), and sequence length
(2,3,4,5,) on RT. Mean RT scores can be seen in Fig. 3.
Reaction times were longer for the TN group than the
control group but the main effect failed to reach conven-
tional levels of significance [F (1,81) = 3.959, p = 0.09,
η2 = 0.035]. There was also a main effect of sequence
length [F (2.61, 211.41) = 7.69, p < 0.001, η2 = 0.085]
caused by differences between sequence lengths of 3 and
4, 4 and 5 and 4 and 6 (all p < 0.01). No group x se-
quence length interaction emerged [F (2.61, 211.41) =
1.44, p = 0.231, η2 = 0.016].
Processing speed
A Mann-Whitney U test revealed a significant difference
in RTs between the groups [U = 465.00, p < 0.001, rank
biserial correlation = − 0.460] with RTs being longer for
the TN group (mean = 3.69 s, SD = 0.86) compared to
Controls (mean = 3.14 s, SD = 0.74).
Inhibition (flankers)
A reciprocal transform was used to achieve homogeneity
of variance and a 2 × 2 mixed ANOVA performed on
these data to analyse the effect of group (TN/Control),
and condition (congruent/incongruent) on RT. A signifi-
cant main effect of group emerged [F (1,81) = 11.45, p <
0.001, η2 = 0.124] with raw RTs for the TN group
(mean = 0.12 s, SD = 0.40) being longer than those for
the Control group (mean = 0.86, SD = 0.24). There was
also a main effect of condition [F (1,81) = 43.70, p <
0.001, η2 = 0.346] with RTs being longer for incongruent
(mean = 1.03 s, SD = 0.37) compared to congruent trials
(mean = 0.95, SD = 0.27). There was no group × condi-
tion interaction [F (1,81) = 1.51, p = 0.223, η2 = 0.012].
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Additional analyses
We first explored monopharmacy versus polypharmacy.
We found no main effect of group for any of the sensori-
motor measures (Aiming, Tracking, and Steering). There
were no differences between groups on reaction time for
Processing Speed or Inhibition tasks. For FDR, BDR and
Corsi (our working memory tests) we found no associa-
tions between group and proportion correct but we did
find a significant main effect of group on reaction time
for both FDR [F (1,40) = 4.198, p < 0.05, η2 = 0.095] and
BDR [F (1,40) = 4.424, p < 0.05, η2 = 0.1]. In both cases
RTs were longer for those undergoing polypharmacy
(FDR mean = 1.146, BDR mean = 1.74) compared to
monopharmacy (FDR mean = 0.896, BDR mean = 1.475).
We next explored whether there would be any differ-
ences between groups taking different types of AED. We
found no main effects of group on any of our measures.
Finally, we tested for an association between dose and
performance and found a significant association on the
Backward Digit Recall task when sequence length was
highest (sequence length 5) with higher doses associated
with poorer performance [r = 0.321; p = 0.049].
Discussion
This study sought to quantify the cognitive and sensori-
motor side effects experienced by individuals being
treated for TN with AEDs. Performance on a battery of
sensorimotor and cognitive tasks of participants with a
diagnosis of TN who were currently undergoing pain
management in the form of AED medication was com-
pared to that of age-matched controls. Results from the
sensorimotor battery showed that the TN participants
(taking AEDs) were significantly worse at tracking a
moving object than Controls (Tracking task) and were
slower than controls to move to a target when it ap-
peared on screen (Aiming task). Our TN group were no
worse than controls in terms of accuracy when steering
through a defined path (Steering task). Findings from
the cognitive battery point towards clear impairments in
the TN group. Participants with TN produced longer re-
action times across all the working memory tasks (FDR,
BDR and Corsi). In addition, the participants in the TN
group were ~ 2–4 times less likely to be “high scorers”
(where the mean proportion correct across the whole
sample was used to categorise participants into high or
low scorers) than participants in the Control group. Fi-
nally, participants in the TN group were significantly
slower than controls in the Processing Speed task, and
significantly less able than controls to inhibit unwanted
responses in the Inhibition (Flankers) task.
The poor tracking performance on our sensorimotor
battery shown by participants with TN is completely
consistent with the extensive literature on AEDs and dis-
rupted cerebellar function [24, 25, 27–29]. This, in
addition to the reduced performance on the Aiming
task, corroborates the accounts often provided by medi-
cated people with TN: that they are experiencing sen-
sorimotor impairments. The tasks in our battery reflect
core components of real-world skills such as driving,
hand-writing, and controlling posture, and our results
can therefore go some way to explaining why people
with TN have reported difficulties with such activities in
the past [6, 17], and are in line with the work of Delcker
et al. [31] who quantified variations in postural stability
in medicated patients with TN. As with the sensori-
motor battery, our findings with regards to performance
on our cognitive battery clearly triangulate evidence
from self-report and qualitative studies [6, 14, 17, 30],
suggesting that patients with TN experience cognitive
impairment as a result of pain medication. Our results
are also consistent with studies reporting the negative
cognitive side effects caused by AEDs in other popula-
tions [18–23].
Our sensorimotor and cognitive measures were de-
signed to capture core abilities that underpin a range of
motor and higher-order cognition tasks. The data can
therefore explain why patients being treated for TN re-
port difficulties with a range of motor and cognitive
tasks. Moreover, a number of activities of daily living re-
quire an interaction between the motor and cognitive
system (e.g. making a cup of tea requires someone to re-
member the sequence of events that result in a palatable
hot beverage but also relies on the motor ability that re-
sults in the requisite actions unfolding across space and
time). The Cognition Action Interaction Theory [37]
suggests that these somewhat different systems (i.e.
motor and higher-order cognition) are intrinsically inter-
twined and impact on one another. This explains why
patients being treated for TN are so severely disabled –
underlying difficulties with both the sensorimotor and
cognitive systems will create problems across a multi-
tude of daily living activities.
The existing research literature suggests that polyphar-
macy is linked to more extreme side effects [23]. We con-
ducted a post-hoc analysis to explore whether there was
any evidence for polypharmacy effects in the TN popula-
tion. The results showed that performance on our phono-
logical working memory tasks (FDR and BDR) was
affected detrimentally to a greater extent in those under-
going polypharmacy compared to monopharmacy. How-
ever, AED dosage is also linked to more extreme side
effects and we could not rule out the possibility that the
polypharmacy was related to dosage. In fact, when we ex-
amined associations between dose and performance a sig-
nificant correlation emerged for the BDR task at the
longest sequence length, where higher dose was associated
with poorer performance. Despite this providing only lim-
ited evidence for the effect of dose, we don’t think it can
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be ruled out due to the nature of our sample (it was var-
ied, and some participants were unable to report exact
dose). A larger clinical trial is required. We also conducted
a post hoc analysis to examine the impact of AED type
(‘sodium’ versus ‘calcium+sodium’ blockers) but found no
group differences. It is not possible to draw conclusions
from this failure to reject the null hypothesis, but the find-
ing does indicate that all AEDs have the potential to cause
side effects of the type reported within this study.
If drug treatment becomes ineffective, or the side effects
of medication are too severe, then surgery can offer an al-
ternative treatment option [8, 38]. Treatments are catego-
rized as either destructive (involving intentional destruction
of sensory nerve function) or non-destructive (involving de-
compression of the trigeminal nerve). Surgical interventions
(such as gamma knife) hold great potential for treating the
pain associated with TN whilst avoiding the potential side
effects of medication. Unfortunately, there are few robust
clinical trials of surgical interventions [8, 39], and the evi-
dence base to support adoption of surgical treatment at the
point of TN diagnosis is lacking. One major problem is that
the side effects of medications for TN (such as AEDs) have
not been measured robustly or objectively (refer to Intro-
duction). It is our hope that the study presented here can
start to address this problem by providing more detail
about the side effects patients can expect. In addition, even
if surgery proves to be the best option, details on AED side
effects remain crucial because pain may recur, and many
patients remain on medication even after surgery because
the pain relief can be delayed for a few months [8] and, in
the absence of a robust RCT, patients (and clinicians) fear
that the pain may return [40].
It is not possible to rule out the possibility that the
poor performance shown by the participants with TN
was due to factors other than their pharmacological
treatment. In order to establish this unequivocally, we
would have needed to ask participants to stop taking
their medication. The ethical justification for this was
absent when we ran the study as we had not yet estab-
lished that there were any objective deficits in sensori-
motor or cognitive function. The present study would
provide such a justification for any scientists who felt
that there were feasible reasons for supposing that the
decrements in sensorimotor and cognitive function were
due to other factors, and such a study should include fur-
ther information on participant clinical characteristics
such as TN duration and history of other diseases. Never-
theless, we would argue that it is likely that the reported
effects are due to the medication. First, our findings are
completely consistent with a large body of evidence sug-
gesting that AEDs cause deficits in sensorimotor and cog-
nitive function. Second, our findings are in accord with
the reports of patients with TN who ascribe these deficits
to the medication. Third, none of our participants were
experiencing an attack of pain during the testing (thereby
ruling out the symptoms of TN as a causal factor in the
observed deficits). Finally, it is very difficult to explain why
problems with the trigeminal nerve would cause deficits of
the type we have identified in the present study.
Conclusions
We undertook the first comprehensive objective evalu-
ation of sensorimotor and cognitive performance in par-
ticipants being treated for TN pain with antiepileptic
drugs relative to age-matched controls and found that
the TN group performed significantly worse than con-
trols on the sensorimotor tracking and aiming tasks and
across all cognitive measures. We suggest that our find-
ings provide strong support for research into alternative
approaches to pain management for people with TN.
Whilst the cost-benefit ratio for AEDs might be justifi-
able for epilepsy, suppressing brain activity to treat TN
pain is potentially sub-optimal, and the current study to-
gether with the existing body of research justifies explor-
ation of alternative options, either in the form of surgery
or non-AED pharmacological interventions that come
with fewer side effects. It is our hope that this work will
lay the foundations for large-scale studies comparing dif-
ferent treatments (both pharmacological and surgical).
Our results have the potential to: (i) help researchers
find more effective pain management strategies; (ii) pro-
vide critical information to patients and clinicians
(thereby allowing them to make effective treatment
choices); and (iii) ultimately reduce or even remove the
side effects experienced by people being treated for TN.
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